在一项试验中,一种新的基因编辑疗法治愈或使64%的T-ALL患者进入深度缓解期. A new gene-edited therapy cured or put into deep remission 64% of T-ALL patients in a trial.

一种叫做BE-CAR7的基因编辑新疗法在治疗T细胞急性淋巴性白血病(T-ALL)方面已经显示出有希望的结果,这是一种罕见和具有攻击性的血液癌,曾经被认为是几乎无法治愈的。 A new gene-edited therapy called BE-CAR7 has shown promising results in treating T-cell acute lymphoblastic leukaemia (T-ALL), a rare and aggressive blood cancer once considered nearly incurable. Great Ormond街医院和伦敦大学学院的科学家开发了“现成”治疗方法,利用经基本编辑的捐赠者T细胞来瞄准癌症,同时保留健康组织。 Developed by scientists at Great Ormond Street Hospital and University College London, the "off-the-shelf" treatment uses base-edited donor T cells to target cancer while sparing healthy tissue. 在对11名病人——9名儿童和2名成人——进行的一项试验中,64%的病人仍然没有疾病,超过80%的病人获得了深度恢复,从而得以成功地进行干细胞移植。 In a trial of 11 patients—nine children and two adults—64% remained disease-free, and over 80% achieved deep remission, enabling successful stem cell transplants. 副作用是轻微的。 Side effects were mild. 第一位病人,Alyssa Tapley,现为16人,于2022年接受治疗,目前处于缓冲期,受启发成为一名研究科学家。 The first patient, Alyssa Tapley, now 16, was treated in 2022 and is in remission, inspired to become a research scientist. 调查结果公布在《新英格兰医学杂志》上,这是治疗选择有限的病人的一项重大进步。 The findings, published in the New England Journal of Medicine, mark a major advance for patients with limited treatment options.